vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Five9, Inc. (FIVN). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 7.8%). Five9, Inc. produced more free cash flow last quarter ($77.3M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 10.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
AXSM vs FIVN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $300.3M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 55.4% |
| Operating Margin | -13.8% | 6.6% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 7.8% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $300.3M | ||
| Q3 25 | $171.0M | $285.8M | ||
| Q2 25 | $150.0M | $283.3M | ||
| Q1 25 | $121.5M | $279.7M | ||
| Q4 24 | $118.8M | $278.7M | ||
| Q3 24 | $104.8M | $264.2M | ||
| Q2 24 | $87.2M | $252.1M | ||
| Q1 24 | $75.0M | $247.0M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $18.0M | ||
| Q2 25 | $-48.0M | $1.2M | ||
| Q1 25 | $-59.4M | $576.0K | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-4.5M | ||
| Q2 24 | $-79.3M | $-12.8M | ||
| Q1 24 | $-68.4M | $-7.1M |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 55.0% | ||
| Q2 25 | — | 54.9% | ||
| Q1 25 | — | 55.0% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | 53.0% | ||
| Q1 24 | — | 53.6% |
| Q4 25 | -13.8% | 6.6% | ||
| Q3 25 | -27.0% | 5.6% | ||
| Q2 25 | -24.5% | -0.6% | ||
| Q1 25 | -46.9% | -1.9% | ||
| Q4 24 | -61.1% | 1.5% | ||
| Q3 24 | -59.8% | -5.8% | ||
| Q2 24 | -89.5% | -7.7% | ||
| Q1 24 | -89.7% | -8.4% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 6.3% | ||
| Q2 25 | -32.0% | 0.4% | ||
| Q1 25 | -48.9% | 0.2% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -1.7% | ||
| Q2 24 | -91.0% | -5.1% | ||
| Q1 24 | -91.1% | -2.9% |
| Q4 25 | $-0.55 | $0.22 | ||
| Q3 25 | $-0.94 | $0.21 | ||
| Q2 25 | $-0.97 | $0.01 | ||
| Q1 25 | $-1.22 | $0.01 | ||
| Q4 24 | $-1.54 | $0.16 | ||
| Q3 24 | $-1.34 | $-0.06 | ||
| Q2 24 | $-1.67 | $-0.17 | ||
| Q1 24 | $-1.44 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $232.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $785.8M |
| Total Assets | $689.8M | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $232.1M | ||
| Q3 25 | $325.3M | $193.4M | ||
| Q2 25 | $303.0M | $205.5M | ||
| Q1 25 | $300.9M | $370.3M | ||
| Q4 24 | $315.4M | $362.5M | ||
| Q3 24 | $327.3M | $291.0M | ||
| Q2 24 | $315.7M | $175.7M | ||
| Q1 24 | $331.4M | $240.2M |
| Q4 25 | $88.3M | $785.8M | ||
| Q3 25 | $73.7M | $775.3M | ||
| Q2 25 | $73.1M | $717.4M | ||
| Q1 25 | $53.2M | $664.3M | ||
| Q4 24 | $57.0M | $622.2M | ||
| Q3 24 | $92.9M | $565.6M | ||
| Q2 24 | $102.9M | $525.9M | ||
| Q1 24 | $144.0M | $483.6M |
| Q4 25 | $689.8M | $1.8B | ||
| Q3 25 | $669.3M | $1.8B | ||
| Q2 25 | $639.8M | $1.7B | ||
| Q1 25 | $596.7M | $2.1B | ||
| Q4 24 | $568.5M | $2.1B | ||
| Q3 24 | $561.5M | $2.0B | ||
| Q2 24 | $548.2M | $1.9B | ||
| Q1 24 | $545.7M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $83.6M |
| Free Cash FlowOCF − Capex | $-18.7M | $77.3M |
| FCF MarginFCF / Revenue | -9.6% | 25.8% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $201.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $83.6M | ||
| Q3 25 | $1.0M | $59.2M | ||
| Q2 25 | $-32.4M | $35.1M | ||
| Q1 25 | $-43.4M | $48.4M | ||
| Q4 24 | $-26.2M | $49.8M | ||
| Q3 24 | $-18.6M | $41.1M | ||
| Q2 24 | $-30.1M | $19.9M | ||
| Q1 24 | $-53.5M | $32.4M |
| Q4 25 | $-18.7M | $77.3M | ||
| Q3 25 | $988.0K | $48.7M | ||
| Q2 25 | $-32.4M | $31.6M | ||
| Q1 25 | $-43.7M | $43.7M | ||
| Q4 24 | $-26.2M | $40.5M | ||
| Q3 24 | $-18.7M | $26.7M | ||
| Q2 24 | $-30.2M | $13.1M | ||
| Q1 24 | $-53.6M | $20.4M |
| Q4 25 | -9.6% | 25.8% | ||
| Q3 25 | 0.6% | 17.0% | ||
| Q2 25 | -21.6% | 11.1% | ||
| Q1 25 | -36.0% | 15.6% | ||
| Q4 24 | -22.1% | 14.5% | ||
| Q3 24 | -17.9% | 10.1% | ||
| Q2 24 | -34.6% | 5.2% | ||
| Q1 24 | -71.4% | 8.3% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.3% | 1.7% | ||
| Q4 24 | 0.0% | 3.3% | ||
| Q3 24 | 0.1% | 5.4% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 4.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.29× | ||
| Q2 25 | — | 30.38× | ||
| Q1 25 | — | 84.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
